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The standard of care for patients with hormone receptor positive, human epidermal growth factor receptor type 2
negative advanced breast cancer is endocrine therapy. Endocrine agents, including aromatase inhibitors, tamoxifen,
and fulvestrant, are often administered alone as first line treatment and demonstrate durable responses with limited
side effects. Endocrine resistance represents a major clinical problem. In the future, poly-endocrine therapy and
combination therapies with biological agents might become valuable options for the first line treatment of hormone
receptor-positive advanced breast cancer. However, it will be critical to develop clinical tools that can reliably identify
the subgroup of patients most likely to benefit from endocrine therapy alone, and those who might benefit from
alternative approaches.
Herein, we will review and discuss current issues in the endocrine treatment of postmenopausal patients with
hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancer.
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Postmenopausal patients with hormone receptor positive
(HR+), human epidermal growth factor receptor type 2
negative (HER2–) tumors represent the majority of patients
with advanced breast cancer (ABC). Despite the sometimes
indolent course of the disease, HR+ HER2– ABC remains
incurable. Current goals of therapy are therefore to prolong
survival and palliate symptoms while maintaining a good
quality of life. In the majority of women with HR+ HER2–
ABC, these goals can be achieved with endocrine therapy,
which represents the standard of care for first line treat-
ment [1]. Available agents for postmenopausal patients
include steroidal (exemestane) and non-steroidal (anastro-
zole and letrozole) aromatase inhibitors (AIs), selective
estrogen receptor modulators (tamoxifen or toremifene),
and the estrogen receptor (ER) down-regulator fulvestrant.* Correspondence: adileo@usl4.toscana.it
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unless otherwise stated.These agents are generally effective and well tolerated, but
not all patients benefit from them equally [1].
At present, due to the lack of predictive biomarkers
that can identify subgroups of patients that will derive
the largest benefit from endocrine therapies, treatment
decisions regarding the choice between endocrine therapy
and chemotherapy are based on clinical criteria such as
disease-free interval, extent of visceral metastatic involve-
ment, and degree of symptoms. When clinical criteria
support its use, endocrine therapy is typically administered
alone, but future options might include poly-endocrine
therapy or combination with new biological agents.Endocrine therapy alone
Tamoxifen has long been established as an effective first
line treatment of postmenopausal women with HR+ ABC
[2]. Phase III trials then compared AIs or fulvestrant to
tamoxifen in such patients demonstrating equivalent
[3-10] or superior efficacy to tamoxifen [5,7,10], being
equally well tolerated, and AIs have become the standardral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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fulvestrant may be superior to AIs in this setting. The
phase II randomized Fulvestrant fIRst-line STudy
(FIRST) trial compared fulvestrant high dose (500 mg)
to anastrozole for first line treatment of postmenopausal
women with HR+ ABC. Clinical benefit rate, the primary
study endpoint was similar for the two groups [3]. How-
ever, at the time of a more mature follow-up, median time
to progression (TTP) was significantly longer for the
patients receiving fulvestrant (23.4 vs. 13.1 months; hazard
ratio (HR), 0.66; 95% CI, 0.47–0.92; P = 0.01) [11]. Up-
dated results, recently presented, showed that also median
overall survival (OS) was significantly longer for fulves-
trant (54.1 months) versus anastrozole (48.4 months; HR,
0.70; 95% CI, 0.50–0.98; P = 0.041) [12]. These results
require confirmation in a phase III trial, which is currently
underway.
Overall, these trials demonstrated that, in a proportion
of women undergoing first line single agent endocrine
treatment, disease remissions lasting more than 12 months
can be observed. Indeed, in the FIRST trial the median
TTP for anastrozole was 13.1 months [11]. In two trials
comparing anastrozole versus tamoxifen, median TTP for
anastrozole was 11.1 months [7] and 8.2 months [6]. How-
ever, a high proportion of patients enrolled in these trials
had not received prior adjuvant endocrine therapy.
Whether the same results would be achieved in patients
who received adjuvant endocrine therapy (commonly with
an AI) remains an open question.
Current clinical tools to distinguish patients who will
benefit from endocrine therapy alone from those who
will require an alternative approach are sub-optimal.
Hierarchical cluster analysis has revealed that HR+ tumors
can be divided into at least two molecular subgroups,
namely luminal A and luminal B [13,14], with distinct
clinical behavior and response to chemotherapy and
endocrine therapy [15]. Additionally, in the adjuvant
setting, molecular signatures are emerging as a power-
ful tool that could aid clinicians in therapeutic decision
[16]. However, the clinical utility of molecular subtypes
and signatures in patients with HR+ HER2– ABC is yet
to be established. The aforementioned clinical trials did
not collect tumor samples, thus subgroup analyses based
on molecular subtypes or any other biomarker could not
be made.
Poly-endocrine therapy
Endocrine agents have different mechanisms of action;
therefore, drug combination strategies of different endo-
crine agents might be an approach to improve the effect-
iveness of endocrine therapy. Indeed, some preclinical
data support poly-endocrine therapy strategies [17], but
results from clinical trials conducted in the metastatic
setting are contradictory [18,19].The Fulvestrant and Anastrozole Combination Therapy
(FACT) trial is a randomized phase III study comparing
fulvestrant low dose (250 mg) and anastrozole in combin-
ation versus anastrozole alone as first line treatment
of postmenopausal women, or premenopausal women
receiving a gonadotropin-releasing hormone agonist,
with HR+ ABC. It enrolled 514 patients and the primary
end point was TTP. TTP, OS, clinical benefit, and object-
ive response rates were neither statistically nor clinically
different between the two treatment groups (HR for TTP,
0.99; 95% CI, 0.81–1.20, P = 0.91; HR for OS, 1.0; 95% CI,
0.76–1.32, P = 1.00) in this trial [18].
Another phase III trial, designed and conducted by the
Southwest Oncology Group (SWOG) Cooperative Group,
randomly assigned 694 postmenopausal women with
HR+ ABC to receive either anastrozole (group 1), or
anastrozole and fulvestrant low dose in combination
(group 2) as first line treatment. The median progression
free survival (PFS) was 13.5 months in group 1 and
15.0 months in group 2 (HR, 0.80; 95% CI, 0.68–0.94;
P = 0.007). OS was also longer in group 2 (47.7 months vs.
41.3 months in group 1; HR, 0.81; 95% CI, 0.65–1.00;
P = 0.05) [19].
The three-arm, phase III SoFEA trial randomized post-
menopausal patients with HR+ ABC to receive fulvestrant
low dose plus anastrozole (n = 243), fulvestrant low dose
plus placebo (n = 231), or exemestane alone (n = 249). It
differed from the FACT and SWOG trials by analyzing a
population that had progressed on non-steroidal AI. No
significant difference in PFS, the primary endpoint, was
seen between the three groups (fulvestrant plus ana-
strozole vs. fulvestrant plus placebo: HR, 1.00; 95% CI,
0.83–1.21; P = 0.98; fulvestrant plus placebo vs. exemes-
tane: HR, 0.95; 95% CI, 0.79–1.14; P = 0.56), nor was an
OS difference seen [20].
It must be highlighted that, in all these trials, the
fulvestrant dose (250 mg) and schedule were chosen
according to the standard in use at the time of studies
design. The phase III Comparison of Faslodex in Recurrent
or Metastatic Breast Cancer (CONFIRM) trial demon-
strated that a higher fulvestrant dosing schedule (500 mg)
was superior to the low dose in terms of PFS and OS
[21,22]. The suboptimal dose of fulvestrant used in these
trials might have therefore influenced the results.
These trials did not collect tumor samples, and analyses
of treatment by luminal subtype or by other tumor-
specific biologic factor were not made, but an unplanned
subgroup analysis of patients enrolled in the SWOG trial
suggested that the majority of benefit seen was in patients
previously untreated with tamoxifen. The median PFS
among women untreated with tamoxifen was 12.6 months
in group 1 versus 17.0 months in group 2 (HR, 0.74; 95%
CI, 0.59–0.92; P = 0.006), while among women previously
treated with tamoxifen, the estimated median PFS was
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95% CI, 0.69–1.15; P = 0.37). The interaction between
treatment and use of prior adjuvant tamoxifen therapy
was not significant (P = 0.22) [19]. In the FACT trial, sub-
group analysis did not suggest any interaction between
previous exposure to endocrine therapy and treatment
activity [18]. However, it included a substantially lower
number of tamoxifen-naïve patients than the SWOG trial
(171 vs. 414 patients, respectively) [18,19]. In the SoFEA
trial, this subgroup analysis was not made, but patients
with tumors with both ER and progesterone receptor (PR)
positivity, favoring a luminal A, more endocrine-sensitive
phenotype, seemed to derive greater benefit from the
combination therapy.
Based on these data, it might be hypothesized that
patients unexposed to prior endocrine therapy and with
highly endocrine-sensitive tumors could derive the largest
benefit from the combination of an AI and fulvestrant.
However, in view of the contradictory results of the trials,
it seems appropriate to wait for further evidence before
considering the combination of AIs and fulvestrant as
standard of care.
Endocrine therapy in combination with biological
agents
Some patients with HR+ ABC show primary resistance
to endocrine therapy, and in the remainder, secondary
resistance ultimately develops, representing a major clinical
problem. The biology of resistance to endocrine therapy
is complex and still not completely elucidated [23].
Preclinical evidence suggests that targeting the phos-
phatidylinositol 3-kinase (PI3K)-Akt-mammalian target
of rapamycin (mTOR) [24] or the cyclin D1-Cyclin-
Dependent Kinases 4 and 6 (CDK4/6) pathway [25] might
increase endocrine sensitivity. Based on this rationale,
randomized clinical trials have recently investigated
whether combination therapies with biological agents
targeting these pathways would improve PFS or OS of
patients with HR+ ABC [26,27].
The phase III BOLERO-2 trial randomized 724 post-
menopausal patients with HR+ HER2– ABC to receive
everolimus, an mTOR inhibitor, and exemestane versus
exemestane and placebo. The primary end point, PFS,
was shown to be significantly improved in patients receiv-
ing everolimus compared to those receiving placebo
according to both local (6.9 vs. 2.8 months; HR, 0.43; 95%
CI, 0.35–0.54; P <0.001) and central assessment (10.6 vs.
4.1 months; HR, 0.36; 95% CI, 0.27–0.47; P <0.001) [26].
However, the combination did not confer a statistically
significant improvement in OS (median OS: 31.0 months
in the everolimus plus exemestane arm vs. 26.6 months
in the exemestane plus placebo arm; HR, 0.89; 95% CI,
0.73–1.10; P = 0.1426) [28]. Given the remarkable PFS
results, everolimus was approved by the Food and DrugAdministration for the treatment of postmenopausal
women with HR+ HER2– ABC in combination with
exemestane, after failure of treatment with letrozole or
anastrozole. However, the toxicity profile of everolimus
is far from ideal. Serious adverse events were higher in
patients receiving everolimus compared to those receiving
placebo (55% and 33%, respectively) and a higher propor-
tion of patients discontinued everolimus because of adverse
events compared to placebo (29% vs. 5%) [28]. For this
reason there is a great interest in identifying biomarkers of
response to screen patients who are likely to derive the
largest benefit from this compound.
mTOR exists in two different complexes, mTORC1 and
mTORC2. Everolimus targets mTORC1, which signals via
two major substrates, the p70 ribosomal protein S6-kinase
(pS6) and the eukaryotic initiation factor 4E binding pro-
tein 1 (4EBP1) [24]. The activity of mTORC1 is regulated
by the serine/threonine kinase Akt, a downstream effector
of PI3-kinases. Activating mutations in the catalytic
subunit of PI3-kinase (PIK3CA) occur in around 40%
of ER+ breast cancers [29], but the hypothesis that
PIK3CA-mutated breast cancers would derive the lar-
gest benefit from mTOR inhibitors was not confirmed
in an exploratory analysis of the BOLERO-2 trial, although
only a fraction of enrolled patients were included [30].
One explanation for these results might be that mutational
status of PIK3CA does not correlate with pathway activa-
tion. A seminal work of Loi et al. indeed demonstrated
that, in ER+ HER2− breast cancer, PIK3CA mutation
surprisingly did not always result in elevated downstream
signaling, and correlated with relatively low mTORC1
signaling [31,32]. Reverse phase protein array data from
the The Cancer Genome Atlas also confirmed that
phospho-AKT, phospho-pS6, and phospho-4EBP1, markers
of PI3K pathway activation, were not necessarily elevated
in PIK3CA mutated luminal A breast cancer [33]. These
data suggest that mutational status of PIK3CA should
be combined with assessment of downstream pathway
activity to have a better prediction of everolimus benefit.
In support of this, Loi et al. [32] showed, in a dataset
derived from patients enrolled in a randomized, double
blind, phase II neoadjuvant trial, that lower scores of a
genomic signature of PIK3CA mutation (PIK3CA-GS)
were able to identify those patients with the largest rela-
tive decreases in Ki67 (a surrogate marker of response)
to letrozole/everolimus (R = −0.43, P = 0.008) compared
with letrozole/placebo (R = 0.07, P = 0.58; interaction test
P = 0.02). However, in a second dataset from pre-surgical
patients using everolimus alone, the PIK3CA-GS was not
correlated with relative change in Ki67 (R =−0.11, P = 0.37).
In both datasets, changes in percentage of Ki67 decrease
were not statistically different between PIK3CA mutant and
wild-type breast cancer [32]. Additionally, translational
studies within the TAMRAD trial, a multicenter phase II
Migliaccio et al. BMC Medicine  (2015) 13:46 Page 4 of 6trial in which postmenopausal women with HR+ HER2–
ABC previously treated with AI were randomly allocated to
receive tamoxifen plus everolimus (n = 54) or tamoxifen
alone (n = 57), have recently shown that the subgroups
most likely to have an improvement in TTP with tamoxifen
plus everolimus therapy compared with tamoxifen alone
were patients with molecular evidence of PI3K pathway
activation (i.e., high phospho-4EBP1, low 4EBP1) [34].
Another important point is that in the BOLERO-2 trial,
PIK3CA mutational status was assessed mainly on pri-
mary tumor tissues [30]. Studies indicate that discordance
in PIK3CA mutational status between primary tumors
and metastases might occur [35-37], suggesting that we
should reassess molecular pathway alterations prior to
starting targeted treatment, either through analysis of
metastatic tissue or, potentially, ‘liquid biopsies’. Indeed,
the feasibility of assessing PIK3CA mutation in circulating
tumor cells [38-41] and circulating free DNA [42-44] has
already been demonstrated.
To further assess the role of PIK3CA mutations in
breast cancer, a mutational analysis of PIK3CA/AKT1
and RAS/RAF was performed on 4,294 primary tumor
samples from postmenopausal patients with ER+ breast
cancer who had been enrolled in the Tamoxifen Exemes-
tane Adjuvant Multinational phase III trial [29]. This
study showed that PIK3CA mutations were more frequent
in low-risk luminal breast cancer and were associated with
significantly improved 5-year distant relapse-free survival
in univariate analysis (HR, 0.76; 95% CI, 0.63–0.91;
P = 0.003) [29]. These results are consistent with previous
findings that PIK3CA mutations are more frequently seen
in luminal A primary tumors and are associated with in-
creased sensitivity to endocrine therapy [31,33,45]. Mayer
and Arteaga suggested, in an accompanying editorial [46],
that the apparent discrepant role of PIK3CA mutations in
early versus late ER+ breast cancer might be explained by a
predominant role of PIK3CA mutations in secondary
endocrine resistance [46]. Data supporting this hypothesis
come from preclinical studies demonstrating an increased
pathway activation in long-term estrogen-deprived breast
cancer cell lines [47] and from an exploratory subgroup
analysis within the TAMRAD trial, which suggested that
the everolimus benefit was seen more in patients with
secondary hormone resistance than those with primary
resistance [48].
In the absence of available biomarkers, clinical consid-
erations regarding the population of the BOLERO-2 trial
should be taken into account when selecting patients
for combination therapy with everolimus. First, 84% of
patients enrolled in the BOLERO-2 trial were sensitive
to prior endocrine therapy. Endocrine sensitivity was
defined as at least 24 months of endocrine therapy
before recurrence in the adjuvant setting or a response
or stabilization for at least 24 weeks of endocrine therapyfor advanced disease [26]. Second, 84% of patients received
everolimus as second line or more of therapy for advanced
disease [26]. Accordingly, in our opinion, the combination
of exemestane and everolimus could be considered an
appropriate second line treatment option for patients
who have demonstrated benefit from first-line endo-
crine therapy.
Several PI3K inhibitors are in clinical development for
patients with HR+ HER2– ABC [49]. Recently, the results
from the FERGI study, a phase II randomized trial of
the PI3K inhibitor pictilisib plus fulvestrant versus ful-
vestrant plus placebo in patients with ER+ AI-resistant
ABC, have been presented. These data showed that the
addition of pictilisib to fulvestrant was associated with
a non-statistically significant improvement in PFS for the
combination versus the control arm (6.2 vs. 3.8 months;
HR, 0.77; 95% CI, 0.50–1.19). The benefit from pictilisib
was independent from PIK3CA mutational status, while
the subgroup of patients that seemed to benefit more from
the addition of pictilisib was that with ER+/PR+ tumors
(PFS, 7.2 vs. 3.7 months in the combination and control
arm respectively; HR, 0.46; 95% CI, 0.27–0.78) [50].
Clinical trials are currently investigating the safety and
efficacy of three CDK4/6 inhibitors, palbociclib, abemaci-
clib, and LEE011, for the treatment of HR+ HER2– ABC
[25]. The compound with more mature clinical results is
palbociclib. The phase II, randomized PALOMA 1 trial
was designed as a two-part study to evaluate palbociclib
in combination with letrozole versus letrozole alone for
first line treatment of postmenopausal patients with
HR+ HER2– ABC. Part 1 of the study enrolled 66 unse-
lected patients, while the Part 2 enrolled 99 patients with
tumors positively screened for cyclin D1 amplification
and/or loss of p16; the primary end point was PFS. The
final analysis showed a statistically significant improve-
ment in PFS for the combination arm versus letrozole arm
(20.2 vs. 10.2 months; HR, 0.488; 95% CI, 0.319–0.748;
one-sided P = 0.0004). When Part 1 and Part 2 were ana-
lyzed separately, treatment effects were maintained (Part
1: HR, 0.299; 95% CI, 0.156–0.572; one-sided P < 0.0001;
Part 2: HR 0.508; 95% CI, 0.303, 0.853; one-sided
P = 0.0046) [27]. Side effects were mainly hematological,
with grade 3/4 neutropenia and leucopenia reported in
54% and 19% of patients receiving palbociclib, respectively
[27]. At present, palbociclib is not registered for the
treatment of breast cancer and confirmatory results from
ongoing phase III trials are eagerly awaited.
Numerous biological agents are currently being investi-
gated in combination with endocrine therapy for the treat-
ment of postmenopausal patients with HR+ HER2– ABC,
including histone deacetylase, Akt, and IGF receptor inhibi-
tors [51,52]. For the future clinical development of these
agents, understanding which subgroup of patients is more
likely to benefit from the combination with endocrine
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with sub-group analyses correlating the clinical activity
with the degree of response to prior endocrine therapies
defined according to standard criteria and ii) with the
identification of biomarkers of response.
Conclusions
Endocrine therapy is the mainstay of first line treatment
for postmenopausal women with HR+ HER2– ABC.
Endocrine agents in mono-therapy demonstrated high
efficacy and tolerability, but endocrine resistance com-
monly arises. Developing clinical tools able to reliably
identify patients that will benefit from endocrine therapy
alone and those that will require different approaches, such
as poly-endocrine therapy or combination with biological
agents, is an urgent clinical need. Studies investigating
poly-endocrine therapy are contradictory and need further
validation. Numerous new agents in combination with
endocrine therapy are in clinical development for patients
with HR+ HER2– ABC. However, when considering a
combination therapy in such patients any additional bene-
fit must be carefully weighed against additional toxicity
and costs.
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